Free Trial
NASDAQ:CYCN

Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis

Cyclerion Therapeutics logo
$2.95
+0.06 (+2.08%)
(As of 11/1/2024 ET)

About Cyclerion Therapeutics Stock (NASDAQ:CYCN)

Key Stats

Today's Range
$2.88
$3.74
50-Day Range
$2.43
$3.16
52-Week Range
$1.75
$5.25
Volume
125,048 shs
Average Volume
6,589 shs
Market Capitalization
$7.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Cyclerion Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
18th Percentile Overall Score

CYCN MarketRank™: 

Cyclerion Therapeutics scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Percentage of Shares Shorted

    0.58% of the float of Cyclerion Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclerion Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclerion Therapeutics has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cyclerion Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cyclerion Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.58% of the float of Cyclerion Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclerion Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclerion Therapeutics has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly.
  • MarketBeat Follows

    1 people have added Cyclerion Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    36.10% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cyclerion Therapeutics' insider trading history.
Receive CYCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYCN Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Cyclerion Therapeutics Inc Ordinary Shares CYCN
Cyclerion Therapeutics Inc (CYCN)
Cyclerion Therapeutics, Inc. (CYCN)
See More Headlines

CYCN Stock Analysis - Frequently Asked Questions

Cyclerion Therapeutics' stock was trading at $3.35 at the beginning of 2024. Since then, CYCN shares have decreased by 11.9% and is now trading at $2.95.
View the best growth stocks for 2024 here
.

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) released its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.53) EPS for the quarter.

Shares of Cyclerion Therapeutics reverse split before market open on Tuesday, May 16th 2023. The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclerion Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), General Electric (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/07/2024
Today
11/02/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYCN
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Net Income
$-5,260,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.62 million
Book Value
$4.62 per share

Miscellaneous

Free Float
1,732,000
Market Cap
$7.99 million
Optionable
No Data
Beta
1.93
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:CYCN) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners